Baird lowered the firm’s price target on Regeneron (REGN) to $652 from $759 and keeps a Neutral rating on the shares. The firm said its Eylea ...

Truist lowered the firm’s price target on Regeneron (REGN) to $975 from $1,004 and keeps a Buy rating on the shares. The firm notes Regeneron ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

TD Cowen also adjusted its price target for Regeneron to $1,030, lowering revenue estimates for the Eylea franchise due to increased market competition. Leerink Partners reduced its price target ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

Market Capitalization: $74.87 Billion Regeneron Pharmaceuticals ... The analyst kept his price target of $1,152 while noting ...

So while biosimilars have caused some price erosion ... acts as a “reverse DCF,” as it reveals what market assumptions are implied by Regeneron’s valuation. This implies that my base ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $762.00 to $834. ...

Regeneron Pharmaceuticals has a 1 year low of $615.00 and a 1 year high of $1,211.20. The company has a market capitalization of $67.45 billion, a PE ratio of 16.12, a price-to-earnings-growth ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion ...